Quark Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Quark Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C5159
◆発行会社(調査会社):GlobalData
◆発行日:2018年9月
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Quark Pharmaceuticals Inc (Quark), a subsidiary of SBI Biotech Co Ltd, is a clinical-stage pharmaceutical company in the development of novel RNAi-based therapeutics. It offers under development products which include PF-655, a synthetic siRNA which is used for the treatment of diabetic macular edema and age-related macular degeneration; and QPI-1002, a synthetic siRNA which is designed for the treatment of acute kidney injury and delayed graft function. The company also provides QPI-1007, a synthetic siRNA which is used for the treatment of ocular neuroprotection and non-arteritic anterior ischemic optic neuropathy. Quark offers its products for multiple unmet medical needs. It works in collaboration with many other companies across the world on its products and technologies. The company has operations in Israel and the US. Quark is headquartered in Fremont, California, the US.

Quark Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Quark Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Quark Pharma Enters into Agreement with Transplant Genomics 11
Suzhou Ribo Life Science Forms Joint Venture With Quark Pharma 12
Licensing Agreements 13
Biocon And Quark Pharma Enter Into Agreement To Develop siRNA Based Therapeutics 13
Quark Pharma Amends Licensing Agreement With Pfizer For PF-655 14
Quark Pharmaceuticals Inc – Key Competitors 15
Quark Pharmaceuticals Inc – Key Employees 16
Quark Pharmaceuticals Inc – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Joint Venture 17
Recent Developments 18
Product News 18
11/13/2017: RiboQuark Pharmaceutical Technology Announces Enrollment of The First Ever Patient in China for a Pivotal Clinical Trial with a siRNA Drug Candidate as Part of a Global Clinical Study of the Ocular Neuroprotectant QPI-1007 18
Clinical Trials 20
Nov 07, 2017: Quark Pharmaceuticals to Present Positive Phase 2 Efficacy And Safety Results Of QPI-1002, A siRNA Targeting p53, For Prevention Of Acute Kidney Injury Following Cardiac Surgery, at the EuroTIDES Conference 20
Nov 04, 2017: Quark Pharmaceuticals Presents Results from a Positive Phase 2 Study of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery at the American Society of Nephrology Meeting 21
Nov 01, 2017: Quark Pharmaceuticals Phase 2 Data on the Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery to Be Presented at the American Society of Nephrology Meeting 22
Jul 27, 2017: Quark Pharmaceuticals Reports Positive Results from a Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury (AKI) in Subjects at High Risk of AKI Following Cardiac Surgery 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Quark Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Quark Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Quark Pharma Enters into Agreement with Transplant Genomics 11
Suzhou Ribo Life Science Forms Joint Venture With Quark Pharma 12
Biocon And Quark Pharma Enter Into Agreement To Develop siRNA Based Therapeutics 13
Quark Pharma Amends Licensing Agreement With Pfizer For PF-655 14
Quark Pharmaceuticals Inc, Key Competitors 15
Quark Pharmaceuticals Inc, Key Employees 16
Quark Pharmaceuticals Inc, Subsidiaries 17
Quark Pharmaceuticals Inc, Joint Venture 17

List of Figures
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Quark Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Quark Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Quark Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • OJSC Dixy Group:企業の戦略・SWOT・財務情報
    OJSC Dixy Group - Strategy, SWOT and Corporate Finance Report Summary OJSC Dixy Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • CareDx Inc (CDNA):企業の製品パイプライン分析2018
    Summary CareDx Inc (CareDx), formerly XDx Inc, is a commercial stage molecular diagnostics company that develops, markets, and delivers diagnostic surveillance solutions. The company offers commercialized testing solution, the AlloMap heart transplant molecular test, is a noninvasive blood test used …
  • AU Optronics Corp (2409):電力:M&Aディール及び事業提携情報
    Summary AU Optronics Corp. (AUO) is a provider of optoelectronic solutions. The company designs, develops, manufactures and assembles a wide range of panel display products. Its panels are primarily used in televisions, monitors, mobile PCs, mobile devices and commercial and other applications. It m …
  • Edan Instruments Inc (300206):企業の製品パイプライン分析2018
    Summary Edan Instruments Inc (Edan Instruments) is a medical equipment provider that offers ECG equipments. The company offers diagnostic ECG, patient monitoring devices, obstetrics and gynaecology monitoring systems, ultrasound imaging, point-of-care testing, in-vitro diagnostics and veterinary equ …
  • ADES International Holding Plc (ADES):企業の財務・戦略的SWOT分析
    ADES International Holding Plc (ADES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • KINeSYS Inc.:企業の戦略・SWOT・財務情報
    KINeSYS Inc. - Strategy, SWOT and Corporate Finance Report Summary KINeSYS Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Alcazar Energy Ltd:電力:M&Aディール及び事業提携情報
    Summary Alcazar Energy Ltd (Alcazar Energy) is a renewable energy company that acquires, develops and operates power generation projects using solar photovoltaic (PV) and onshore wind technologies. The company offers services such as business development, asset management, investment and financing, …
  • Laboratorio Teuto Brasileiro SA-製薬・医療分野:企業M&A・提携分析
    Summary Laboratorio Teuto Brasileiro SA (Teuto), a subsidiary of Pfizer Inc is a drug company that develops, manufactures, and markets generic and over the counter products. The company’s products include aerodini aerosol salbutamol sulphate, afopic folic acid, albentel albendazole, acetato de dexam …
  • GrafTech International Ltd:企業の戦略・SWOT・財務分析
    GrafTech International Ltd - Strategy, SWOT and Corporate Finance Report Summary GrafTech International Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Taiflex Scientific Co Ltd (8039):企業の財務・戦略的SWOT分析
    Taiflex Scientific Co Ltd (8039) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Anadarko Petroleum Corp (APC):企業の財務・戦略的SWOT分析
    Anadarko Petroleum Corp (APC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Time Technoplast Ltd.:戦略・SWOT・企業財務分析
    Time Technoplast Ltd. - Strategy, SWOT and Corporate Finance Report Summary Time Technoplast Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Sirtex Medical Ltd (SRX):企業の財務・戦略的SWOT分析
    Summary Sirtex Medical Ltd (Sirtex Medical) is a medical device company that develops and markets device for the treatment of liver cancer. The company’s sir-spheres microsphere is a medical device, which is used in selective internal radiation therapy for liver tumors. Its product Y-90 resin micros …
  • Naftogaz of Ukraine:企業の戦略的SWOT分析
    Naftogaz of Ukraine - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Al Ahli Bank of Kuwait KSC:企業の戦略・SWOT・財務情報
    Al Ahli Bank of Kuwait KSC - Strategy, SWOT and Corporate Finance Report Summary Al Ahli Bank of Kuwait KSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Asahi Kasei Corp (3407)-エネルギー分野:企業M&A・提携分析
    Summary Asahi Kasei Corp (Asahi Kasei), formerly Asahi Chemical Industry Co. Ltd., manufactures, processes, and sells chemical products. It is a holding company of Asahi Kasei Group. The product portfolio of the company includes polymers, acrylonitrile, styrene, diagnostic reagents, foam insulation …
  • Telekom Malaysia Bhd (TM):企業の財務・戦略的SWOT分析
    Telekom Malaysia Bhd (TM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • National Company KazMunayGas:石油・ガス:M&Aディール及び事業提携情報
    Summary National Company KazMunayGas (KazMunayGas) is a state-owned, vertically integrated oil and gas company. It carries out the acquisition, exploration, development, production, processing, transportation, refining and export of hydrocarbons. The company also produces petrochemicals, stores and …
  • Bioasis Technologies Inc (BTI):企業の財務・戦略的SWOT分析
    Summary Bioasis Technologies Inc (BTI) is a developer and commercialize of pharmaceutical products and diagnostic technologies for central nervous system diseases and disorders. The company’s transcend program describes the proprietary carrier, p97 to deliver therapeutics and imaging agents across t …
  • Albéa Beauty Holdings S.A.:企業の戦略・SWOT・財務情報
    Albéa Beauty Holdings S.A. - Strategy, SWOT and Corporate Finance Report Summary Albéa Beauty Holdings S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆